<?xml version="1.0" encoding="UTF-8"?>
<ref id="b16-1031654">
 <label>16.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Daver</surname>
    <given-names>N</given-names>
   </name>
   <name>
    <surname>Boumber</surname>
    <given-names>Y</given-names>
   </name>
   <name>
    <surname>Kantarjiian</surname>
    <given-names>H</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>A Phase l/ll study of the mTOR inhibitor everolimus in combination with hyperCVAD chemotherapy in patients with relapsed/refractory acute lymphoblastic leukemia</article-title>. 
  <source>Clin Cancer Res</source>. 
  <year>2015</year>;
  <volume>21</volume>(
  <issue>12</issue>): 
  <fpage>2704</fpage>â€“
  <lpage>2714</lpage>.
  <pub-id pub-id-type="pmid">25724525</pub-id>
 </mixed-citation>
</ref>
